Cleveland Biolabs (CBLI)

Company Profile

Cytocom Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Collins, Colorado and currently employs 2 full-time employees. The company went IPO on 2006-07-21. Cytocom, Inc., formerly Cleveland BioLabs, Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing small molecule immunotherapies, which targets autoimmune, inflammatory, infectious diseases and cancers. Its advanced immunomodulating multi-receptor system (AIMS) platform is a drug discovery and development platform, which is designed to restore immune homeostasis. Its immunomodulatory drugs are developed using AIMS platform, which adjusts immune responses to halt or slow disease progression. Its clinical-stage development programs are focused on treating Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer. The Company’s programs include CYTO-200 AIMS Program, CYTO-400 AIMS Program and CYTO-600 Program. The firm also has a platform of toll-like immune receptors (TLR4, TLR5 and TLR9), which address the conditions such as radiation sickness and cancer treatment side effects.

Company Info

Cleveland Biolabs

2537 Research Boulevard, Suite 201

Fort Collins COLORADO 14203

P: 18886138802.0

CEO: Christopher Zosh

Employees: 2

Website: https://www.cytocom.com/